At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 74 enrolled
Drug / intervention
Dasatinib +2 moredrug
Likely dose
Dasatinib 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: A Phase 2, Single-Center, 20-week, Open-Label, Randomized Controlled Trial.
In Brief
A Phase 2 clinical trial evaluating Dasatinib, Quercetin, and 1 other intervention for Healthy. Completed, enrolled 74 participants across 1 site.
Detailed Summary
To determine if senolytic drugs reduce senescent cell burden and reduce bone resorption markers/increase bone formation markers in elderly women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartJun 2020
Primary CompletionJun 2023
TodayJul 2026
First PostedMar 18, 2020
Enrollment StartJun 9, 2020
Primary CompletionJun 6, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 6.3 years ago
Interventions
Dasatinibdrug
Dasatinib will be supplied as 100 mg tablet white to off-white, biconvex, oval, film- coated
Quercetindrug
Quercetin will be supplied as quercetin phytosome (sophora japonica concentrate (leaf) / phosphatidylcholine complex from Sunflower) 250 mg
Fisetindrug
Fisetin will be supplied in 100 mg capsules to be administered orally